Erythropoietin Drugs Market by Product Type, Distribution Channel, End User 2022-2027

1
Global Erythropoietin Drugs Market Research and
Forecast Report 2022-2027




Author Elena Anderson Marketing Manager IMARC
Group
2022 IMARC All Rights Reserved
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2
About IMARC Group
Report Description
International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all regions
and industry verticals to identify their
highest-value opportunities, address their most
critical challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Erythropoietin Drugs Market Research
Report 2022-2027 According to the latest report
by IMARC Group, titled "Erythropoietin Drugs
Market Global Industry Trends, Share, Size,
Growth, Opportunity and Forecast
2022-2027," the global erythropoietin drugs
market size reached US 9.8 Billion in 2021.
Erythropoietin (EPO) is a hormone produced
naturally by kidneys to stimulate the production
of red blood cells (RBCs) in the body. Its
deficiency or excess leads to severe medical
conditions, such as low hemoglobin levels and
kidney diseases. EPO drugs, also known as
haematopoietin, are injectable drugs used to cure
anemia and increase RBC production. They are
widely used to treat anemic conditions caused by
chronic renal disease, cancer treatment,
myelodysplasia, medicine side effects, and
surgery. They also help reduce infections in
acquired immune deficiency syndrome (AIDS) and
pre-operative blood transfusion. EPO drugs mimic
the naturally occurring erythropoietin and
stimulate the bone marrow to produce more
RBCs. Request for a PDF sample of this report
https//www.imarcgroup.com/erythropoietin-drugs-ma
rket/requestsample

4
Report Description and Highlights
Report Description
Global Erythropoietin Drugs Market Trends The
widespread prevalence of chronic diseases, such
as cancer, AIDS, and kidney problems, is one of
the primary factors driving the market growth.
EPO drugs are widely used to treat anemic
conditions induced by end-stage renal disease
(ESRD), antiretroviral treatments (ART),
chemotherapy, radiotherapy, and other cancer
treatments. In addition to this, rising product
utilization to treat critically ill patients
owing to its anti-ischemic, anti-apoptotic, and
regenerative effects in various tissues, such as
lungs, kidneys, nervous system, pancreas, and
retina, is acting as another growth-inducing
factor. Furthermore, the rapid
commercialization of highly efficient
biosimilars, which are easy to switch,
cost-effective, and require less approval time,
is providing an impetus to the market growth. In
line with this, the widespread product
application in chemotherapy cycles, along with
the increasing incidences of end-stage renal
diseases (dialysis), is favoring the market
growth. Additionally, the recent repurposing of
EPO drugs for treating diabetes mellitus (DM) due
to its cytoprotective effect that enhances
cardiac function, reduces fatigue, and improves
cognition in DM patients is positively
influencing the market growth. Moreover, the
implementation of various government initiatives
to incentivize research on chronic diseases
through grants, drug exclusivity, fee waivers,
and tax credits is propelling the market growth.


5
Report Description and Highlights
Report Description
Other factors, including rising awareness
regarding the benefits of EPO therapeutics, the
increasing geriatric population in need of
surgical procedures, and rising strategic
collaborations among drug manufacturers due to
high return on investment (ROI), are anticipated
to drive the market growth. Looking forward,
IMARC Group expects the market to reach US 13.8
Billion by 2027, exhibiting at a CAGR of 5.75
during 2022-2027. View Report TOC, Figures and
Tables https//www.imarcgroup.com/erythropoietin-
drugs-market

6
Report Description and Highlights
Report Description

• Key Market Segmentation
• The research report includes the following
  segments
• Breakup by Drug Class
• Biologics
• Biosimilars
•  
• Breakup by Product Type
• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Others
• Breakup by Application
• Hematology
• Kidney Disorder
• Cancer
• Others

7
Report Description and Highlights
Report Description

•  
• Breakup by End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Breakup by Region
• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa

8
Key Questions Answered in the Report
Report Description

• Competitive Landscape with Key Players
• Amgen Inc
• Biocon Limited
• Dr. Reddys Laboratories Ltd
• F. Hoffmann-La Roche AG
• Intas Pharmaceuticals Ltd
• Johnson Johnson
• LG Chem Ltd
• Pfizer Inc
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd
•  

9
Key Questions Answered in the Report
Report Description

• How has the global erythropoietin drugs market
  performed so far and how will it perform in the
  coming years?
• What has been the impact of COVID-19 on the
  global erythropoietin drugs market?
• What are the key regional markets?
• What is the breakup of the market based on the
  drug class?
• What is the breakup of the market based on the
  product type?
• What is the breakup of the market based on the
  application?
• What is the breakup of the market based on the
  end user?
• What are the various stages in the value chain of
  the industry?
• What are the key driving factors and challenges
  in the industry?
• What is the structure of the global
  erythropoietin drugs market and who are the key
  players?
• What is the degree of competition in the
  industry?
•  

10
Table of Contents
Report Description
1    Preface2    Scope and Methodology    2.1
   Objectives of the Study    2.2  
 Stakeholders    2.3    Data Sources       
2.3.1    Primary Sources        2.3.2  
 Secondary Sources    2.4    Market Estimation 
      2.4.1    Bottom-Up Approach        2.4.2  
 Top-Down Approach    2.5    Forecasting
Methodology3    Executive Summary4  
 Introduction    4.1    Overview    4.2    Key
Industry Trends5    Global Erythropoietin Drugs
Market    5.1    Market Overview    5.2  
 Market Performance    5.3    Impact of
COVID-19    5.4    Market Forecast

11
Table of Contents
Report Description
6    Market Breakup by Drug Class    6.1  
 Biologics        6.1.1 Market Trends       
6.1.2 Market Forecast    6.2    Biosimilars   
    6.2.1 Market Trends        6.2.2 Market
Forecast7    Market Breakup by Product Type   
7.1    Epoetin-alfa        7.1.1 Market Trends 
      7.1.2 Market Forecast     7.2  
 Epoetin-beta        7.2.1 Market Trends       
7.2.2 Market Forecast    7.3  
 Darbepoetin-alfa        7.3.1 Market Trends   
    7.3.2 Market Forecast         Click here to
visit the complete table of content with list of
figures and tables https//www.imarcgroup.com/ery
thropoietin-drugs-market/toc

12
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
13
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
14
Report Description and Highlights
Report Description

2022 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
15

Contact Us